UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Company as specified in charter) |
(State or another jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip code)
+
(Company’s Telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chi Yuen Leong as Chief Executive Officer and Director.
On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.
Mr. Leong has no family relationship with any director or executive officer of the Company. He was not involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.
Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company’s inception to August 2022 and has been working with and guiding the Company’s successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to our board of directors.
Mr. Leong entered into an employment agreement with the Company dated October 12, 2023, and agreed to receive an annual compensation of $24,000.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIONEXUS GENE LAB CORP |
| |
|
|
| |
Date: October 16, 2023 | By: | /s/ Chi Yuen Leong |
|
| Name: | Chi Yuen Leong |
|
| Title: | Chief Executive Officer |
|
3 |
Cover |
Oct. 12, 2023 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | BIONEXUS GENE LAB CORP. |
| Entity Central Index Key | 0001737523 |
| Document Type | 8-K |
| Amendment Flag | false |
| Entity Emerging Growth Company | true |
| Document Period End Date | Oct. 12, 2023 |
| Entity Ex Transition Period | false |
| Entity File Number | 333-229399 |
| Entity Incorporation State Country Code | WY |
| Entity Tax Identification Number | 35-2604830 |
| Entity Address Address Line 1 | Unit 2, Level 10, Tower B, Avenue 3 |
| Entity Address Address Line 2 | The Vertical Business Suite II Bangar South |
| Entity Address Address Line 3 | No. 8 Jalan Kerinchi |
| Entity Address City Or Town | Kuala Lumpur |
| Entity Address Country | MY |
| Entity Address Postal Zip Code | 59200 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Local Phone Number | 1221-26512 |
| Security 12b Title | Common Stock, no par value |
| Trading Symbol | BGLC |
| Security Exchange Name | NASDAQ |
| City Area Code | 60 |